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Abstract
Approximately 5 10  of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/  rearrangement (  ). We determined the– % MYC MYC  +
prognostic significance of  rearrangement in patients with relapsed/refractory DLBCL prospectively treated by R-ICE orMYC
R-DHAP followed by high-dose therapy and autologous stem cell transplantation. Twenty-eight (17 ) of the 161 patients analyzed%
presented a  rearrangement, targeted as either simple hit (25 ) or complex hits (n 75 ) including /MYC  + % = % MYC BCL2, MYC/BCL6,
and . Results were statistically highly concordant in matched primary and relapsed biopsies (n 45). Compared toMYC/BCL2/BCL6 =
the  DLBCL patients, the  DLBCL patients presented with a more elevated lactico-deshydrogenase level (p .0006) and aMYC  − MYC  + =
more advanced age-adjusted international pronostic index (p .0039). The 4-year PFS and OS were significantly lower in the  = MYC  +
DLBCL patients than those in the  DLBCL patients, with rates of 18  vs. 42  (p .0322), and of 29  vs. 62  (p .0113),MYC  − % % = % % =
respectively. Type of treatment, R-DHAP or R-ICE had no impact on survivals, with 4-year PFS rates of 17  vs. 19  and 4-year OS% %
rates of 26  vs. 31 . In conclusion,  rearrangement is an early event in DLBCL.  DLBCL patients have a significant% % MYC MYC  +
inferior prognosis than  DLBCL patients. Their outcome was not influenced by the proposed salvage therapy.MYC  −
MESH Keywords Adult ; Aged ; Antibodies, Monoclonal, Murine-Derived ; administration & dosage ; adverse effects ; Antineoplastic Combined Chemotherapy Protocols 
; administration & dosage ; adverse effects ; Carmustine ; administration & dosage ; adverse effects ; Chemotherapy, Adjuvant ; Cisplatin ; administration & dosage ; adverse
effects ; Combined Modality Therapy ; Cytarabine ; administration & dosage ; adverse effects ; Dexamethasone ; administration & dosage ; adverse effects ; Etoposide ; 
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administration & dosage ; adverse effects ; Female ; Genes, myc ; physiology ; Hematopoietic Stem Cell Transplantation ; methods ; Humans ; Ifosfamide ; administration &
dosage ; adverse effects ; Immunotherapy ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; genetics ; mortality ; therapy ; Male ; Melphalan ; administration & dosage ; 
adverse effects ; Middle Aged ; Podophyllotoxin ; administration & dosage ; adverse effects ; Salvage Therapy ; Transplantation, Autologous ; Treatment Failure ; Young Adult
INTRODUCTION
Diffuse large B-cell lymphomas (DLBCLs) are recognized as a heterogeneous group of aggressive lymphomas, with numerous
clinical, morphological, immunohistochemical and molecular subtypes, as demonstrated by the last World Health Organisation (WHO)
classification, which defines no less than 13 subentities[1]. Among the DLBCLs, between 4  to 14  harbor a  rearrangement (% % MYC MYC
DLBCL) as evaluated by fluorescence in situ hybridization (FISH) 2,6 . These cases differ from the defined borderline  cases, which are[ ] “ ”
considered unclassifiable B-cell lymphomas having features that are intermediate between DLBCL and Burkitt lymphomas 7,8  and[ ]
presenting with a mixture of medium-to-large-sized cells, a high proliferation rate and an 8q24/  translocation in 35 to 50  ofMYC %
cases[7,8]. In contrast to the Burkitt lymphomas,  aberrations in DLBCL are usually associated with multiple cytogeneticMYC
abnormalities and other genetic lesions, such as concurrent  and/or  translocations, so-called double-hit  or triple-hitBCL2 BCL6 “ ” “ ”
lymphomas[5,9 13].–
The clinical importance of the presence of an  aberration in DLBCL has been recently suggested in series of patients analyzed inMYC
first-line therapy. Patients with  DLBCL have been reported in one series 6 to present a disease similar to DLBCL but without an MYC [ ]
 aberration (  DLBCL) showing no differences in median age, LDH (Lactico-deshydrogenase), IPI (International PrognosticMYC MYC
Index) or performance status. The only difference noted was a higher proliferative rate, as determined by Ki67 staining in excess of 80 ,%
in patients harboring a  aberrations[6]. In other series, patients with  DLBCL present with a more aggressive disease includingMYC MYC
particular clinical features such as poor performance status and bone marrow involvement[5], or more advanced stage, higher IPI, and a
higher age-adjusted IPI[2]. With respect to survival, all series agree in reporting that these patients with  DLBCL have poorerMYC
outcomes than patients with  DLBCL[5,6], regardless of the treatment regimen included, such as cyclophosphamide, doxorubicin,MYC  −
vincristine, prednisone (CHOP), and CHOP plus etoposide (CHOEP)[4,5]. The presence of  aberrations retains its negative prognosticMYC
significance even in patients treated with rituximab and anthracycline-based immuno-chemotherapy[2,3,6]. However, one recent study
reported that a regimen based on DA-EPOCH-R (Dose-adjusted etoposide, vincristine, and doxorubicine for 96 hours with bolus of
cyclophosphamide and oral prednisone, plus Rituximab) in first-line may improve the outcome of these patients[14]. Importantly, the
prognostic impact of the presence of  aberrations appears to be independent from other factors such as IPI, and bone marrowMYC
involvement[6]. Furthermore, the negative impact of  aberrations supersedes the favorable prognosis of GC DLBCL, with aMYC
significantly worse event-free and overall survivals compared with either the non-GC phenotype or  DLBCL[4,6].MYC  −
The purpose of this study was to screen for  aberrations in a selected population of patients with relapsed/refractory DLBCLs toMYC
determine the frequency of this occurrence and whether there were any defining phenotypic or clinical features in the  group and toMYC  +
assess the prognostic impact of  aberrations in these relapsed/refractory DLBCL patients treated prospectively with R-DHAPMYC
(rituximab, dexamethasone, aracytine, cisplatin) vs. R-ICE (rituximab, ifosfamide, etoposide, carboplatin) that was followed by high-dose
therapy plus autologous stem cell transplantation (HDT/ASCT).
MATERIALS AND METHODS
The patients studied in the present biological analyses were a subset of the 477 patients analyzed in the CORAL study[15], which
enrolled patients aged 18 to 65 years old who presented a relapsed/refractory CD20  DLBCL to compare the efficacy of R-ICE and+
R-DHAP followed by HDT/ASCT (part 1) and to test maintenance with or without rituximab (part 2). The study was registered under
European Union Drug Regulating Authorities Clinical Trials (EudraCT) No.2004-002103-32 and ClinicalTrials.gov NCT 00137995 and
was conducted in accordance with Good Clinical Practice rules. All patients gave written informed consent to participate and to provide
tissue material for biological studies.
Fluorescent in situ hybridization (FISH) analysis
Histological material was available for a total of 161 patients at diagnosis (n 121 cases) and/or at relapse (n 87 cases) for FISH= =
analysis. FISH analysis was performed on TMA or full slides of paraffin-embedded 2 3- m tissue sections using the break-apart probes– μ
for /8q24 (Abbott, France and Germany). Further analyses were conducted using break-apart probes for /18q21 and c-MYC BCL2 BCL6
/3q27 (Abbott, France and Germany). Samples were analyzed with an AxioImager.M1 epifluorescence microscope (Carl Zeiss, Germany).
Images were captured with a 63X or 100X oil objective and analyzed with the Isis software (MetaSystems, Germany). The hybridization
signal scoring was performed according to Haralambieva et al.[16], with a normal cutoff value of 10 .%
Morphology, immunohistochemistry and Cell of origin (COO) algorithms
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A panel of five hematopathologists (JB, PG, HUV, CS, SC) conducted a central review to confirm the diagnosis of CD20+
DLBCL[1,17]. None of the 161 cases were intermediate cases between DLBCL and Burkitt lymphoma: all were diagnosed as DLBCL.
The same panel of hematopathologists centrally evaluated the immunostainings and the FISH results. Immunostainings against CD10
(clone 56C6, dilution 1/50; Novocastra, Newcastle, United Kingdom), BLC2 (bcl-2 124; Dako, Glostrup, Denmark), IRF4/MUM1 (clone
Mum1p, dilution 1/20; Dako A/S), BCL6 (clone P1F6, dilution 1/10; Dako A/S, Glostrup, Denmark), and FOXP1 (clone JC12, dilution
1/50; A.H. Banham, Oxford, United Kingdom) were performed using 3- m sections either from either full slides or from tissueμ
microarrays (TMAs) containing two or three representative 0.6-mm cores of routinely FFPE (formaldehyde fixed-paraffin embedded)
tissue from each cases. The results of each immunostaining trial were considered positive when greater than 30  of the lymphoma cells%
were stained. The tissue quality was morphologically evaluated on H-E staining. All evaluable cases were given a secondary classification
according to the COO algorithms previously described by Hans et al.[18], Muris et al.[19], and Nyman et al.[20].
Microarray procedures and analyses
A subset of 37 patients was selected with both the  FISH analysis and the GEP (gene expression profiling) analysis realized. AMYC
total of 47 samples (20 primary biopsies, 17 relapse biopsies and 5 matched cases) were then included. The microarray procedures are
previously described[17]. Briefly, total RNA quantity and initial quality were estimated with a NanoDrop ND-1000 spectrophotometer, ®
and RNA quality was further assessed by electrophoresis (Agilent 2100 Bioanalyzer: Agilent Technologies, Mississauga, ON). The
Agilent Whole Human Genome microarray (G4112F) and a gene-voting method were used to determine the COO based on the genes’
discriminating GCB/ABC signatures previously reported by Alizadeh et al. 21 to define a GCB/ABC predictor similar to that described our[ ]
previous work[17]. The samples were then classified based on this predictor. The microarray data were submitted to the Gene Expression
Omnibus (GEO) (GSE26812).
Statistical analysis
As previously reported[17], no statistical variations in each biological parameter analyzed by IHC obtained at diagnosis and at relapse
were detected among the matched pairs (data not shown). This finding allowed us to analyze all data in a similar manner, irrespective of
whether they were generated from diagnostic or relapse biopsies. All survival analyses were performed on an intention-to-treat basis.
Patient characteristics and complete remission rates were compared by the chi-squared and Fisher exact tests. Progression-free survival
(PFS) was defined as the time from study entry until disease progression or death. Overall survival (OS) was defined as the time from the
start of treatment until death. Survival functions were estimated using the Kaplan-Meier method and compared with the log-rank test[22].
Differences between the results of comparative tests were considered significant at a 2-sided  <0.05. Because the CORAL trial was notP
stratified by biological data, we controlled for the effects of prognostic factors on outcome due to sampling fluctuations in the treatment
groups with a multivariate analysis of survival in a Cox model[23]. All statistical analyses were performed using SAS 9.13 (SAS Institute,
Cary, NC) and S-Plus 6.2 (MathSoft, Cambridge, MA) software
RESULTS
Overall, 161 of the 477 patients included in the CORAL trial were included based on a successful FISH analysis at defining the
presence or absence of an  rearrangement using paraffin-embedded-tissue (TMA or full slides). One hundred and twenty-one casesMYC
were collected at diagnosis (primary biopsy), and 84 cases were collected at relapse (relapse biopsy), including 45 matched cases with the
biopsies obtained at both diagnosis and relapse.
In total, 28 of the 161 (17 ) cases disclosed an  rearrangement. Twenty-one of the  cases (75 ) had one or more% MYC MYC  + %
concurrent translocations, implicating either  in t(14;18), or  in t(3;14), so-called double-hits , or  in t14;18) and  inBCL2 BCL6 “ ” BCL2 BCL6
t(3;14), so-called triple-hits . The  rearrangements were mostly translocations (Table 1). In 2 cases, we observed multiple copies of “ ” MYC
. Considering the 45 matched cases, the results for the primary and secondary biopsies were similar in 87  of the cases (Wilcoxon sMYC % ’
paired ranked test p .99). At diagnosis, 6 (6/45, 13 ) cases were  cases, and 39 (39/45, 87 ) were  cases. At relapse 8 (8/45,= % MYC  + % MYC  −
18 ) cases were  cases, and 37 (39/45, 82 ) were  cases.% MYC  + % MYC  −
Clinical Characteristics
 DLBCL patients were predominantly male (71 ) with a median age of 55 years (range: 44 65 years). Compared with  MYC  + % – MYC  −
DLBCL patients, the  DLBCL patients presented with more advanced disease, showing a high aaIPI in 54  of the patients (pMYC  + % =
.0039), and an elevated LDH level in 77  of them (p .0006) (Table 2). There was no difference in the frequency of extranodal site% =
involvement. The number of patients with early relapse, defined as relapse less than 12 months from the end of first-line treatment, was
identical in both groups (  cases, 61  vs.  cases, 50 , p .3196).MYC  + % MYC  − % =
IHC and cell of origin
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 DLBCL cases expressed significantly more CD10 than  DLBCL cases (60  vs. 34 , respectively p .0137) as shown inMYC  + MYC  − % % =
Table 3. Immunohistochemical expression of BCL6, MUM/IRF4, and FOXP1 in  tumor cells were observed in 77 , 33 , 81  ofMYC  + % % %
the cases, respectively without significant differences compared with the  tumor cells.MYC
The COO phenotype assignments by IHC based on Hans s algorithm, Muris s algorithm, and Nyman s algorithm, were available for’ ’ ’
152 cases. Based on Hans s algorithm,  DLBCL cases were classified as GC in 63  of the cases, whereas 46  were classified as’ MYC  + % %
GC in the MYC DLBCL cases. Thirty-seven cases were assigned by GEP. Based on the GEP predictor for the GCB/ABC genotype, 3  −
 DLBCL cases exhibited a GCB profile.MYC  +
Impact on response and survival of MYC rearrangements in patients with relapsed/refractory DLBCL
At salvage therapy, 83 patients were treated with R-DHAP and 78 were treated with R-ICE. After the induction treatment (R-ICE or
R-DHAP), the overall response rate (ORR) was lower in the cohort of patients with  DLBCL than in the cohort of patients with MYC  +
 DLBCL (50  vs. 69 , respectively, p .0519); see Table 2.MYC  − % % =
The complete response rate (CR) after induction treatment (R-ICE or R-DHAP) was significantly lower in patients with  MYC  +
DLBCL than in those with  DLBCL (25  vs. 45 , p .0497). After the induction treatment, fewer  DLBCL patientsMYC  − % % = MYC  +
underwent HDT/ASCT than those  DLBCL patients (43  vs. 60 , p .0928).MYC  − % % =
The 4-year PFS and OS were significantly lower in the  DLBCL patients than in the  DLBCL patients (Figure 1), withMYC  + MYC  −
rates of 18  vs. 42  (p .0322), and 29  vs. 62  (p .0113), respectively. The same result was observed for the  DLBCL patients% % = % % = MYC  +
who underwent the HDT/ASCT. These  DLBCL patients treated with HDT/ASCT had a 4-year PFS and OS rates of 14  and 23 ,MYC  + % %
respectively.
No difference was observed when we compared the group of cases with  rearrangements consisting of single chromosomalMYC
aberrations and the group of cases with  rearrangements presenting as complex aberrations with dual and triple translocations. TheMYC
4-year PFS (16  vs. 17 , p .8700) and OS (25  vs. 33 , p .7677) rates were similar in the single-hit and in the complex-hit groups.% % = % % =
Impact of R-ICE and R-DHAP treatment
The type of treatment (R-ICE or R-DHAP) did not influence the outcomes of the  DLBCL patients. The corresponding ORRMYC  +
and CR rates were 50  and 25  in the  DLBCL patients, respectively, with no differences observed after R-ICE (ORR  40 , CR% % MYC  + = %
23 ) or R-DHAP (ORR  62 , CR  26 ) (ORR p .1607; CR, p .8268) (Table 4). In patients with  DLBCL, the CR rates were 35% = % = % = = MYC  −
 and 54  with R-ICE and with R-DHAP respectively (p .0250).% % =
With respect to survival, R-ICE and R-DHAP yielded similar results in the cohort of patients with  DLBCL. The 3-year PFSMYC  +
was at 19  in the R-ICE arm and 17  in the R-DHAP arm (Figure 2). The respective 3-year OS rates were 26  and 31  (Figure 2). In% % % %
the cohort of patients with MYC DLBCL, the 3-year PFS and OS rates were 31  and 51  in the RICE arm and 53  and 71  in the − % % % %
RDHAP arm, respectively.
Impacts of the GCB and non-GCB phenotypes
When we classified the entire cohort of the 161 patients into subgroups based on the GCB vs. non-GCB phenotype using Hans s’
algorithm, the GCB DLBCL patients treated with R-DHAP had a significantly higher complete remission rate than the non-GCB DLBCL
patients (49  vs. 31 , p .0348), as previously reported 17 (Table 4).% % = [ ]
Multivariate analysis using a Cox proportional hazard model including the presence or absence of  aberrations, the type ofMYC
induction treatment, R-ICE vs. R-DHAP, and the GC vs. non-GC phenotype based on Hans s algorithm confirmed that the only significant’
factor for both PFS and OS was the presence of a  aberration, with a relative risk RR  of 1.8 for PFS (p  .0248), and an RR of 2 forMYC [ ] =
OS (p  .0162).=
DISCUSSION
A limited number of studies evaluating the prognostic importance of  status have been reported to date but all were in the contextMYC
of first-line treatment based on CHOP or CHOP-like regimens, with or without rituximab[2,4 6,11,13]. This report is the first study to–
analyze the impact of  aberration in patients less than 65 years old with relapsed/refractory DLBCL.MYC
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Several characteristics of the clinical presentation of the disease and the patients with  DLBCL at relapse are interesting toMYC+
highlight. First, the median ages  DLBCL and  DLBCL patients are similar. Second, the times to relapse between the end ofMYC  + MYC  −
first-line treatment and the time of relapse treatment, which correspond to the randomization in the CORAL trial, are similar in both
patient cohorts. Third, the clinical presentation of  DLBCL seems more aggressive than that of  DLBCL, as reportedMYC  + MYC  −
previously in a series of patients undergoing first-line treatment[2,5,6].  DLBCL LDH levels were more often elevated, as were theMYC  +
IPI scores. However, we did not observe more patients with more than one extranodal site, representing 29  of the patients in our series.%
All of the prior studies performed in first-line treatment using anthracycline-based regimens with or without rituximab found a strong
prognostic impact of  gene rearrangement. In the context of relapsed/refractory DLBCL, the outcomes of the  DLBCL patientsMYC MYC  +
were also found to be worse than those of the  DLBCL patients. This was true regardless of the type of induction treatments, i.e.MYC  −
R-ICE or R-DHAP. Complete remission rates were low, accounting for approximately 25  of the  DLBCL patients. Less than half% MYC  +
of these responder  DLBCL patients followed the complete course of treatment and received the high-dose treatment withMYC  +
autologous stem cell transplantation, compared with 60  in the  DLBCL group.% MYC  −
With the caveat that this study examined a relatively small number of cases, the type of aberrations of  gene (single-, double- orMYC
triple-hit) had no impact on these results. The role of the  aberration appeared to be the same whether the aberration was extra copiesMYC
of the gene or a chromosomal translocation implicating . We observed no differences when  aberrations were associated asMYC MYC
complex hits with other aberrations including  and  gene rearrangements.BCL2 BCL6
Taking the opportunity to analyze the tumors at both diagnosis and relapse in the 45 matched cases,  aberrations were found beMYC
present or absent in a similar ways in the biopsies at diagnosis and those at relapse. This suggests that the occurrence of  aberration isMYC
probably an early event in the pathogenesis of this tumor.
Regarding the phenotypes of the cases, an  aberration was strongly associated with the GCB phenotype, showing significantMYC
associations with CD10 expression and a GCB phenotype based on a GEP analysis. The  cases were more often classified as GCBMYC  +
based on Hans s algorithm. The outcome of the patients with GCB phenotypes based on Hans s algorithm who were treated with R-DHAP’ ’
was better than the outcome of the patients with non-GCB phenotype, except when  gene was rearranged.  rearrangement wasMYC MYC
found to counteract the good prognosis associated with the GCB profile and R-DHAP treatment.
In conclusion,  rearrangements were found to be present in 17  of the patients with relapsed/refractory DLBCL, defining a smallMYC %
group of patients with a very bad prognosis independently from the known prognostic risk factors and regardless the type of treatment
proposed, even in the case of HDT/ASCT. Moreover, our results suggest that this genetic event is probably an early event in the
pathogenesis of the tumor and is associated with a GCB phenotype. Finally, our data together with those of previous studies highlight the
fundamental role of  in the prognosis of DLBCL, particularly GCB-like DLBCL. This finding suggests the importance of performingMYC
FISH analysis for MYC rearrangement in highly proliferative DLBCL and emphasizes the need for new treatments for patients with  MYC
DLBCL. +
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Figure 1
Progression-free survival and overall survival according to the presence ( ) or the absence ( ) of  aberrationMYC+ MYC− MYC
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Figure 2
Progression-free survival and overall survival according to the treatment and the presence ( ) or absence ( ) of  aberrationMYC+ MYC− MYC
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Table 1
Type of /8q24 aberration and its association with other rearrangements including /18q21 and /3q27 in the relapsed/refractory DLBCLMYC BCL2 BCL6
n ( )%
Total of patients analysed 161 (100)
Presence of /8q24 aberrationMYC 28 (17)
 Simple hit : /8q24 onlyMYC 7
 Complex hits 21
  Double hit 
  MYC/8q24 and /18q21BCL2 13
  MYC/8q24 and /3q27BCL6 4
  Triple hit 
  MYC/8q24 and /18q21and /3q27BCL2 BCL6 4
No rearrangement 133 (83)
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Table 2
Baseline characteristics of patients with either  or  relapsed/refractory DLBCLMYC  + MYC  −
No. of patients
 DLBCLMYC  +  DLBCLMYC  − p
n 28= % n 133= %
Sex
 Male 20 71 77 59 .1835
 Female 8 29 56 41
Age
 Median 55 54 .1135
 Range 44 65– 19 65–
PS(ECOG)
 0 1– 23 82 122 92 .1128
 2 3– 5 18 11 8
Ann Arbor Stage
 I II– 8 29 63 48 .0200
 III IV– 20 71 70 52
Elevated LDH 20 77 53 40 .0006
Extranodal site > 1 8 29 33 25 .1821
aaIIPI
 0 1– 12 46 94 71 .0081
 2 3– 14 54 38 29
Initial response
 CR-CRU 16 57 81 61 .3669
 CRU 2 7 18 14
 PR 5 18 18 14
 Stable disease 2 7 4 3
 Progression 5 18 12 9
Time to relapse .3196
 < 12 months 17 61 67 50
 ≥ 12 months 11 39 66 50
Prior rituximab treatment 20 71 80 60 .2635
Treatment at relapse
 RICE 15 54 63 53 .5505
 RDHAP 13 46 70 47
Response at induction
 CR/CRU 7 25 60 45 .0497
 PR 5 18 20 15
 Overall response (CR/CRU/PR) 14 50 92 69 .0519
Transplant 12 43 80 60 .0928
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Table 3
Immunohistochemical staining results, cell of origin classification based on GC/nonGC algorithms, according the presence or the absence of  aberrationMYC
Cases
 MYC +  MYC −
Parameter n ( )% n ( )% p
Immunohistochemistry
CD10 27 127
 Positive 16 60 84 66 .0137
 Negative 11 40 43 34
BCL6 26 128
 Positive 20 77 88 69 .4065
 Negative 6 23 40 31
MUM1/IRF4 27 128
 Positive 9 33 62 48 .1523
 Negative 18 67 66 52
FOXP1 (Barrans) 27 128
 Positive 22 81 86 67 1420
 Negative 5 19 42 33
BCL2 27 128
 Positive 22 81 31 76 .5239
 Negative 5 19 97 24
GC/nonGC algorithm publication
Hans et al. 27 125
 GC 17 63 57 46 .1017
 Non GC 10 37 68 54
Muris et al. 27 126
 Group 1 22 82 80 63 .0719
 Group 2 5 19 46 37
Nyman et al. 23 123
 ABC 5 22 30 24 .7846
 Others 18 78 93 76
Cell of origin based on GEP
3 24
 GC 3 100 13 54 -
 ABC 0 0 11 46
GC indicates germinal center; GEP gene expression profiling, and ABC, activated B-cell
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Table 4
Complete response considering type of treatment (R-ICE vs R-DHAP) and phenotype characteristics including cell of origin based on Hans s algorythm and MYC aberration’
Treatment
Complete response p (X2)
R-ICE
n 78 ( )= %
R-DHAP
n 83 ( )= %
Patients analysed by FISH 29 (37) 35 (42) .3187
Hans COO
 GC 24 (31) 41 (49) .0348
 Non GC 37 (47) 32 (38) .2931
 aberrationMYC
 Presence 20 (26) 19 (23) .8268
 Absence 27 (35) 45 (54) .0250
GC  Germinal Center=
